What happens if the research materials you share are used beyond the agreed scope or become the basis for another party’s innovation?

The exchange of biological materials is essential to healthcare and biotechnology research. However, without clear legal safeguards, the transfer of these materials can lead to disputes over their use, ownership of research outcomes, and intellectual property rights.

A Material Transfer Agreement (MTA) helps prevent these risks by defining the rights, obligations, and permitted use of transferred materials. But why is an MTA so important, and what are the consequences of an inadequately drafted agreement? This article explores the answers.

Understanding the Role of a Material Transfer Agreement (MTA) in Healthcare and Biotechnology Research

A Material Transfer Agreement (MTA) is a legal contract governing the transfer and receipt of research materials between two parties. It defines the parties’ rights and obligations, as well as the limitations on the use of the transferred materials throughout the research collaboration.

In practice, the materials exchanged may include biological tissues, human specimens, cell cultures, microorganisms, DNA, RNA, plasma, serum, and other research materials. These materials often possess significant strategic value because they are closely associated with research findings, pharmaceutical development, medical devices, and biotechnology innovations. For research institutions and companies operating in this sector, engaging a healthcare and medical law firm ensures compliance with applicable regulations.

In Indonesia, the use of MTAs is supported by Minister of Agriculture Regulation No. 15/Permentan/OT.140/3/2009 on Guidelines for Drafting Material Transfer Agreements (“Minister of Agriculture Regulation No. 15/2009”). This regulation establishes the MTA as the legal basis for transferring research materials to ensure legal certainty regarding the rights and obligations of the parties involved.

The requirement is further reinforced under Article 340 paragraph (3) of Law No. 17 of 2023 on Health (“Health Law”), which provides that:

“The transfer and use of materials in the form of clinical specimens and biological materials, information content, and/or data outside the territory of Indonesia must be accompanied by a Material Transfer Agreement prepared based on the principles of equitable benefit-sharing, safety, and public benefit.”

The implementation of MTAs is also supported by the Health Development Policy Agency (Badan Kebijakan Pembangunan Kesehatan/BKPK) under Indonesia’s Ministry of Health, which provides MTA services for both the transfer and receipt of health research materials. Through this mechanism, every transfer of research materials is expected to comply with safety standards, research ethics, and the protection of Indonesia’s national interests.

An MTA also serves to clarify ownership of research outcomes, prevent the misuse of research materials, and provide a legal framework for resolving future disputes concerning the use of transferred materials.

What Clauses Should Be Included in a Material Transfer Agreement?

Fundamentally, an MTA is a contract. Accordingly, its preparation remains subject to the general principles of Indonesian contract law under the Indonesian Civil Code (Kitab Undang-Undang Hukum Perdata/KUHPerdata), particularly Article 1320, which sets out the validity requirements of an agreement, and Article 1338, which provides that:

“All agreements lawfully entered into shall bind the parties as law. Such agreements may not be revoked except by mutual consent or on grounds prescribed by law. Agreements must be performed in good faith.”

To provide comprehensive legal protection, an MTA should include, at a minimum, the following key provisions:

First, the identities of the parties and their respective authority to transfer and receive the research materials. This clause ensures that each party has the legal capacity to enter into the agreement.

Second, a detailed description of the transferred materials. The type, quantity, characteristics, and intended purpose of the materials should be clearly defined to avoid differing interpretations.

Third, restrictions on the use of the materials. This provision should specify that the materials may only be used within the agreed scope of research and may not be transferred to any third party without the material provider’s prior written consent.

Fourth, confidentiality obligations. In many healthcare and biotechnology research projects, the transferred materials are accompanied by confidential research data or commercially valuable information that requires legal protection.

Fifth, provisions governing intellectual property rights. This clause determines ownership of research results, inventions, patents, and scientific publications arising from the use of the transferred materials. A well-drafted MTA can be complemented by broader corporate and commercial legal services to ensure comprehensive protection.

In addition, an MTA should also regulate liability for damage to the materials, procedures for returning or destroying the materials upon completion of the research, dispute resolution mechanisms, and the governing law, particularly where the collaboration involves institutions from different jurisdictions. In this context, civil litigation and dispute resolution services may be relevant if conflicts arise from the agreement.

What Are the Risks of an Improperly Drafted MTA?

An MTA that is incomplete or inadequately drafted can expose the parties to significant legal and commercial risks. These risks may not only affect the relationship between the parties but also jeopardize the continuity of the research itself.

One of the most common risks is the use of research materials beyond the agreed purpose. Without clear contractual limitations, the recipient may utilize the samples for unrelated research without the provider’s authorization.

Likewise, the absence of clear provisions on intellectual property ownership may result in disputes over inventions, patents, and scientific publications. Additional risks arise where research materials are transferred to third parties without authorization or are used in a manner that violates research ethics or data protection principles.

Disputes involving research materials frequently stem from MTAs that fail to clearly define the parties’ respective rights and obligations. As a result, disagreements may arise regarding the permissible use of the materials, ownership of research outcomes, and the commercialization of innovations developed through the collaboration.

Conclusion

A Material Transfer Agreement (MTA) is far more than an administrative formality. It is a vital legal instrument that establishes legal certainty regarding the parties’ rights and obligations, defines the permissible scope of material use, and safeguards the research outcomes generated through the collaboration.

For this reason, every MTA should be carefully drafted and tailored to the specific characteristics of the research partnership. Engaging legal counsel at the contract drafting stage can help identify potential legal risks, develop appropriate contractual provisions, and ensure that the MTA complies with applicable laws and regulations. Licensing and compliance expertise is particularly valuable when the transferred materials cross international borders or involve regulated substances. With a well-structured MTA in place, research collaborations can proceed more securely, provide greater legal certainty, and significantly reduce the likelihood of future disputes.

***

Regulations

References

Pertanyaan yang Sering Diajukan

What is a Material Transfer Agreement (MTA)?

A Material Transfer Agreement (MTA) is a legal contract that governs the transfer and receipt of research materials between two parties. It defines the rights, obligations, and limitations on the use of the transferred materials throughout the research collaboration.

Is an MTA required by law in Indonesia?

Yes. Under Article 340 paragraph (3) of Law No. 17 of 2023 on Health, the transfer and use of clinical specimens and biological materials outside Indonesia must be accompanied by an MTA prepared based on the principles of equitable benefit-sharing, safety, and public benefit.

What materials are typically covered by an MTA?

Materials covered may include biological tissues, human specimens, cell cultures, microorganisms, DNA, RNA, plasma, serum, and other research materials used in healthcare and biotechnology research.

What are the key clauses that should be included in an MTA?

An MTA should include the identities of the parties, a detailed description of the materials, restrictions on use, confidentiality obligations, intellectual property provisions, liability clauses, procedures for returning or destroying materials, dispute resolution mechanisms, and governing law.

What are the risks of an improperly drafted MTA?

Risks include unauthorized use of research materials beyond the agreed scope, disputes over intellectual property ownership, unauthorized transfer of materials to third parties, violations of research ethics, and legal uncertainty that may jeopardize the continuity of research collaborations.

For comprehensive support in drafting, reviewing, or negotiating Material Transfer Agreements, SIP Law Firm offers integrated retainer and general counsel services that cover contract drafting, IP protection, and regulatory compliance. Contact SIP Law Firm for professional legal counsel tailored to your healthcare and biotechnology research needs.

Material Transfer Agreement (MTA): A Legal Safeguard for Healthcare and Biotechnology Research